MindMaze Therapeutics Holding (RLFTF)

[sjoseph]

Relief Therapeutics is a virtual company »
Raghuram Selvaraju, VRP of Relief Therapeutics, gives an insight into the corona project.

Several pharmaceutical companies have signed up to distribute Aviptadil. «We are hiring a re
Several pharmaceutical companies have signed up to distribute Aviptadil. "We are seeing a lot of interest," says Chairman Raghuram Selvaraju. (Image: Anthony Anex / Keystone)
The hope for effective means has already driven the shares of some small pharmaceutical companies to unimagined heights during the corona crisis. But none shows a more phenomenal price increase of more than 40,000% than Relief Therapeutics. On the one hand, this is due to the fact that it was valued at just CHF 2 million on the stock exchange at the beginning of the year, and on the other hand, it is due to the prospect of a drug against Covid-19.

Since the company announced the first results of its active ingredient Aviptadil (RLF-100) last week, the shares have taken off. In an interview with “Finanz und Wirtschaft”, Chairman of the Board of Directors Raghuram Selvaraju is confident: “We hope that Aviptadil delivers better results than Remdesivir.” Gilead's drug is the first and so far only in a scientific study to have a positive effect on disease progression and has received emergency approval.